Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 March 2021 to Question 166476, what equality impact assessment has been done on HIV prevention drug PrEP only being available in sexual health services; and what assessment he has made of the (a) benefits and (b) risks for diverse communities of PrEP being available in (i) GP practices, (ii) pharmacies, and (iii) other NHS services.

No equality impact assessment has been completed. Public Health England, in collaboration with stakeholders, is currently developing a monitoring and evaluation framework for the routine commissioning of the HIV prevention drug pre-exposure prophylaxis (PrEP). This will use established surveillance systems and include measures of PrEP need and use among key population groups to inform equitable delivery and access. The provision of PrEP, including the settings in which PrEP should be made available outside of specialist sexual health services, will be considered as part of the development of the Sexual and Reproductive Health Strategy and HIV Action Plan, which we plan to publish in 2021.